Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Escitalopram on Sperm DNA Fragmentation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03527043
Recruitment Status : Recruiting
First Posted : May 16, 2018
Last Update Posted : April 24, 2019
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Tracking Information
First Submitted Date  ICMJE January 19, 2018
First Posted Date  ICMJE May 16, 2018
Last Update Posted Date April 24, 2019
Actual Study Start Date  ICMJE October 1, 2017
Estimated Primary Completion Date December 1, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 22, 2019)
Proportion of patients converted from normal to abnormal sperm DNA fragmentation from baseline to 6 weeks [ Time Frame: 0 (baseline), 6 weeks ]
TUNEL assay for sperm DNA fragmentation
Original Primary Outcome Measures  ICMJE
 (submitted: May 15, 2018)
Proportion of patients converted from normal to abnormal sperm DNA fragmentation from baseline to 6 weeks [ Time Frame: 6 weeks ]
TUNEL assay for sperm DNA fragmentation
Change History Complete list of historical versions of study NCT03527043 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 22, 2019)
  • Absolute change in sperm DNA fragmentation [ Time Frame: 0 (baseline), 6, 10 weeks ]
    TUNEL assay for sperm DNA fragmentation
  • Changes in sperm motility [ Time Frame: 0 (baseline), 6, 10 weeks ]
    Percentage of motile sperm in semen analysis
  • Changes in progressive motility [ Time Frame: 0 (baseline), 6, 10 weeks ]
    Percentage of progressive motile sperm in semen analysis
  • Changes in viability [ Time Frame: 0 (baseline), 6, 10 weeks ]
    Percentage of viable sperm in semen analysis
  • Changes in concentration [ Time Frame: 0 (baseline), 6, 10 weeks ]
    Sperm concentration (number of sperm/mL) in semen analysis
Original Secondary Outcome Measures  ICMJE
 (submitted: May 15, 2018)
  • Absolute change in sperm DNA fragmentation from baseline to 6 and 10 weeks [ Time Frame: 0, 6, 10 weeks ]
    TUNEL assay for sperm DNA fragmentation
  • Changes in sperm motility from baseline to 6 and 10 weeks [ Time Frame: 0, 6, 10 weeks ]
    Percentage of motile sperm in semen analysis
  • Changes in progressive motility from baseline to 6 and 10 weeks [ Time Frame: 0, 6, 10 weeks ]
    Percentage of progressive motile sperm in semen analysis
  • Changes in viability from baseline to 6 and 10 weeks [ Time Frame: 0, 6, 10 weeks ]
    Percentage of viable sperm in semen analysis
  • Changes in concentration from baseline to 6 and 10 weeks [ Time Frame: 0, 6, 10 weeks ]
    Sperm concentration (number of sperm/mL) in semen analysis
Current Other Pre-specified Outcome Measures
 (submitted: April 22, 2019)
  • Change in serum testosterone (ng/dL) [ Time Frame: 0 (baseline), 6, 10 weeks ]
    Serum testosterone measurement
  • Change in serum luteinizing hormone (LH) (mIU/mL) [ Time Frame: 0 (baseline), 6, 10 weeks ]
    Serum Luteinizing hormone measurement
  • Change in serum follicle-stimulating hormone (FSH) (mIU/mL) [ Time Frame: 0 (baseline), 6, 10 weeks ]
    Serum follicle-stimulating hormone measurement
  • Change in serum prolactin (ng/mL) [ Time Frame: 0 (baseline), 6, 10 weeks ]
    serum prolactin measurement
  • Change in International Index of Erectile Function Survey [ Time Frame: 0 (Baseline), 6, 10 weeks ]
    International Index of Erectile Function (IIEF) Survey. Severe Erectile Dysfunction (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), and no Erectile Dysfunction (22-25)
Original Other Pre-specified Outcome Measures
 (submitted: May 15, 2018)
  • Change in serum testosterone (ng/dL) from baseline to 6 and 10 weeks [ Time Frame: 0, 6, 10 weeks ]
    Serum testosterone measurement
  • Change in serum luteinizing hormone (LH) (mIU/mL) from baseline to 6 and 10 weeks [ Time Frame: 0, 6, 10 weeks ]
    Serum Luteinizing hormone measurement
  • Change in serum follicle-stimulating hormone (FSH) (mIU/mL) from baseline to 6 and 10 weeks [ Time Frame: 0, 6, 10 weeks ]
    Serum follicle-stimulating hormone measurement
  • Change in serum prolactin (ng/mL) from baseline to 6 and 10 weeks [ Time Frame: 0, 6, 10 weeks ]
    serum prolactin measurement
  • Change in International Index of Erectile Function Survey from baseline to 6 and 10 weeks [ Time Frame: 0, 6, 10 weeks ]
    International Index of Erectile Function Survey
 
Descriptive Information
Brief Title  ICMJE Impact of Escitalopram on Sperm DNA Fragmentation
Official Title  ICMJE Assessing the Impact of Escitalopram on Sperm DNA Fragmentation: A Randomized Placebo Controlled
Brief Summary Double-blind placebo-controlled randomized trial of daily escitalopram for 6 weeks in healthy men with normal semen analyses and no psychiatric history of depression, bipolar, mania or suicidal ideation. Hormone profiles, semen analysis, sperm DNA fragmentation, and sexual function will be measured at baseline, after 6 weeks of therapy, and 4 weeks after discontinuation of therapy (10 weeks into study).
Detailed Description SSRI medications, specifically escitalopram is a very commonly prescribed medication among men of reproductive age. Significant evidence exists that they may be harmful for paternal fertility potential in both animal and human studies. However, high quality data is lacking, particularly among commonly used SSRI's such as escitalopram. As such, it is important to properly evaluate the potential effect of escitalopram in a randomized placebo controlled fashion. Results will be important in guiding urologists, psychiatrists and family practitioners regarding discussion surrounding SSRI use in their patients interested in fertility.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Sperm DNA Fragmentation
  • Infertility, Male
Intervention  ICMJE
  • Drug: Escitalopram
    10mg by mouth daily for 6 weeks
  • Other: Placebo
    matched placebo control by mouth for 6 weeks
Study Arms  ICMJE
  • Experimental: Escitalopram
    10mg by mouth daily for 6 weeks
    Intervention: Drug: Escitalopram
  • Placebo Comparator: Placebo
    Matched placebo control by mouth for 6 weeks.
    Intervention: Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 18, 2019)
70
Original Estimated Enrollment  ICMJE
 (submitted: May 15, 2018)
45
Estimated Study Completion Date  ICMJE December 1, 2020
Estimated Primary Completion Date December 1, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Normal semen analyses, or semen analyses with at least 5 million sperm
  • Normal TUNEL value (<7%)
  • Willing to engage in at least weekly sexual activity, with a partner or alone for the duration of the 10-week study

Exclusion Criteria:

  • Azoospermia or severe oligospermia (<5million sperm per semen analysis)
  • Presently attempting to conceive pregnancy
  • Sexual dysfunction preventing ability to provide semen analysis throughout study or engage in weekly sexual activity
  • Current psychiatric disorder including: bipolar, mania, depression, generalized anxiety, social phobia, panic attacks, obsessive compulsive disorder, and schizophrenia.
  • Family history of bipolar disorder, or suicide (including 2nd degree relatives)
  • Present use of psychotropic agents (prescription or herbal) or anticonvulsants
  • Use of sleeping pills
  • Alcohol consumption greater that 2oz/day
  • Use of illicit drugs
  • Inability to read, follow instructions or complete questionnaires in English.
  • Use of hormonal medications in past 3 months (androgens, androgen blockade, anabolic steroids, estrogens, herbal)
  • Use of medications to enhance sexual function
  • History of chemotherapy or pelvic radiation
  • Use of Monoamine Oxidase inhibitors (MAOi's) or tricyclic antidepressants (TCAs) within 14 days
  • Liver disease
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Adaobi Onunkwo 646-962-0534 ado2007@med.cornell.edu
Contact: Julie Carter (212) 746-5706 juc2032@med.cornell.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03527043
Other Study ID Numbers  ICMJE 1608017504
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Weill Medical College of Cornell University
Study Sponsor  ICMJE Weill Medical College of Cornell University
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Ryan Flannigan, MD Weill Cornell Medicine
Principal Investigator: Peter Schlegel, MD Weill Cornell Medicine
Principal Investigator: Phil Bach, MD Weill Cornell Medicine
PRS Account Weill Medical College of Cornell University
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP